UNSPSC 51152000: Neuromuscular blocking agents

This classification denotes drugs that interrupt transmission of nerve impulses at the skeletal neuromuscular junction. they can be of two types, competitive, stabilizing blockers (neuromuscular nondepolarizing agents) or noncompetitive, depolarizing agents (neuromuscular depolarizing agents). both prevent acetylcholine from triggering the muscle contraction and they are used as anesthesia adjuvants, as relaxants during electroshock, in convulsive states, etc.

UNSPSC 51152000 Neuromuscular blocking agents is a Class code, but the recent state and local opportunities tagged under it do not align with the code's nominal pharmaceutical scope. The Seminole County, Florida IFB solicits naloxone and drug deactivation systems for community health support, while the Texas Health and Human Services Commission RFI seeks vendor capabilities for direct-to-manufacturer prescription programs. Neither opportunity involves neuromuscular blocking agents. The code shows minimal relevant recent activity, with these two postings appearing to reflect tagging misalignment rather than genuine procurement demand for the drug class itself.

The two opportunities originate from different issuing-body types — a county government procurement (Seminole County) and a state health agency (Texas HHS Commission) — but neither is actually buying neuromuscular blocking agents. The Seminole County opportunity, IFB 60459723LAS posted June 30, 2026, with a response deadline of July 26, 2023, targets annual procurement of naloxone units and deactivation systems through competitive sealed bidding, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The Texas RFI HHS0017013, posted April 3, 2026, with the same response deadline, is an exploratory market-intelligence effort designed to inform future formal solicitations rather than a competitive procurement. Based on available records, this Class code does not currently reflect active state and local buying activity for neuromuscular blocking agents themselves.